Foresite's new $775-million Fund V as well as a $193.5-million fund for nurturing earliest-stage startups, called the Fund V Opportunity Fund, bring the firm's assets under management to approximately $4 billion . . .
- 10x Genomics
- Financing
- GEN Edge
- Genome Editing
- OMICs
- Genomics
- Precision Medicine
- Single Cell Technology
- Single-Cell Genomics
- Synthetic Biology
- Venture Capital
Flush with Cash, Foresite Aims to Live Up to Its Name
With $1B in new funds, VC firm eyes precision medicine, single-cell, and synthetic biology
Foresite Capital’s management team. Top row [L.-R.]: Vikram Bajaj, PhD, managing director and co-founder and CEO of Foresite Labs; Jim Tananbaum, MD, founder and CEO; Matthew Buten, managing director. Bottom row [L.-R.]: Michael Rome, PhD, managing director; Alisa Mall, managing director; Dennis D. Ryan, MBA, CFO and managing director; Dorothy Margolskee, MD, managing director. [Foresite Capital]
